Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2003;101:722-725
© 2003 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ekerhovd, E.
Right arrow Articles by Norström, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ekerhovd, E.
Right arrow Articles by Norström, A.

ORIGINAL RESEARCH

Gemeprost Versus Misoprostol for Cervical Priming Before First-Trimester Abortion: A Randomized Controlled Trial

E. Ekerhovd, MD, PhD, N. Radulovic, MD and A. Norström, MD, PhD

From the Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden.

Address reprint requests to: Erling Ekerhovd, MD, PhD, Sahlgrenska University Hospital, Department of Obstetrics and Gynecology, Göteborg University, Göteborg, SE-413 45, Sweden; E-mail: erling.ekerhovd{at}obgyn.gu.se.

OBJECTIVE: To compare the efficacy of 400 µg of misoprostol with that of 1 mg of gemeprost as cervical priming agents when administered vaginally 3 to 4 hours before first-trimester vacuum aspiration abortion.

METHODS: In a prospective controlled trial 90 nulliparous women who requested termination of pregnancy before 12 weeks’ gestation were randomized to receive vaginally either misoprostol or gemeprost for cervical priming. The force to dilate the cervix was measured by the use of a cervical tonometer connected to Hegar dilators from 3 to 10 mm. The main outcome measures were baseline cervical dilation; the peak force to dilate the cervix at 8, 9, and 10 mm; and the cumulative force to dilate the cervix to 10 mm.

RESULTS: Baseline cervical dilation did not differ significantly between the women who received misoprostol and those who were treated with gemeprost. Neither the peak force required to dilate the cervix at 8, 9, and 10 mm nor the cumulative force to dilate the cervix to 10 mm showed any significant difference between the two groups.

CONCLUSION: Vaginally administered misoprostol (400 µg) is as effective as gemeprost (1 mg) for cervical priming 3 to 4 hours before surgical termination of first-trimester pregnancies.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Obstetricians and Gynecologists.